A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 | stella

Learn About Find trials matched to me

About Learn Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 | stella

Back to Hepatic Impairment trials

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(4 sites)

United States

Research Site, Chandler, Arizona

Research Site, Rialto, California

Research Site, Miami Lakes, Florida

Research Site, San Antonio, Texas

Key details

Phase

Safety & dosing

Sponsor

AstraZeneca

Enrollment target

~28 participants

Started

March 2026

Primary completion

February 2027

Age range

18 Years – 85 Years

Last updated on clinicaltrials.gov in May 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

AstraZeneca Clinical Study Information Center

AstraZeneca

View full record on ClinicalTrials.gov

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Enrollment status is pulled from ClinicalTrials.gov and may not reflect real-time availability. If a trial appears full when you reach out, the team will let you know.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.